Otsuka Pharmaceutical is ending its alliance with Akebia Therapeutics, a move that comes less than two months after the FDA rejected their partnered anemia drug, vadadustat, and asked for another clinical trial. Otsuka alleges unspecified breaches of the agreement by Akebia, and ending the alliance early could spare it from spending hundreds of millions of dollars more on the drug.
Webinar: Date: June 9, 2022 Time: 11am ET / 8am PT
Drug innovation and the product pipeline in the cardiometabolic space is lagging due to the inherent time and cost of evidence generation needed for regulatory evaluation and approvals.
There are several factors that can impact delivery success, drive up costs and potentially delay time to market. They include:
Longer trial duration
Intensive trial-related testing
Poor medication adherence
Delayed detection of key signals linked to endpoint capture
Under-representation of the patient population for whom the treatment is intended
We will also highlight how (Medable) is working to address drug development challenges and improve the patient experience in the context of clinical studies. with its best-in-class digital products geared for the cardiometabolic sector.
A webinar sponsored by Medable will explore challenges of drug innovation in the cardiometabolic space and how connected devices could make evidence collection less costly and more efficient to support regulatory evaluation and approvals.
Chimerix is selling global rights to smallpox drug Tembexa, the biotech's only FDA-approved product, as a way to fund clinical development of a therapy in pivotal testing for a rare type of brain cancer. The deal marks Chimerix's nearly complete departure from the antiviral work that defined the company for most of its history.
Covid changed things for medical affairs teams at pharmaceutical companies, causing was a fundamental shift in the way they worked and functioned. The role of the medical science liaison—a key member of the medical affairs team—has also evolved.
An analytics-driven A/R strategy can significantly improve collections in today's healthcare environment. This article goes over the pillars of this approach as well as what metrics should be focused on in implementing such a strategy.
The Boston-based company announced Monday that it had received 510(k) clearance from the FDA for its Caries Assist, software that uses AI to aid dentists in detecting cavities. In May last year, Overjet received FDA clearance for AI-powered technology used in the diagnosis and treatment of gum disease.
Every health plan is required to use real-time benefit tools, which allow physicians to access drug pricing and a patient's benefit information at the point of care. But, to date, RTBTs haven't delivered on the promised savings.
This event will bring together healthcare futurists, novel employers, payers, providers, and forward-thinking investors and entrepreneurs who support the broad transformation being spearheaded by digital health technologies.
MedCity News 611 Broadway New York, NY 10012 United States
You received this email because you are subscribed to MedCity Daily Digest from MedCity News.
Update your email preferences to choose the types of emails you receive.
No comments